Lipella Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration (FDA) has approved an Investigational New Drug (IND) application for a multi-center, phase-2a, dose-escalation clinical trial to assess the safety and efficacy of LP-310 in patients with symptomatic oral lichen planus (OLP), a highly morbid condition with no effective treatment. In March 2023, Lipella created a five-member Scientific Advisory Board in Oral Health, made up of a group of highly regarded experts in oral medicine, to focus on the development of LP-310. This team helped craft the clinical strategy and will be involved in the recruitment of high-quality clinical sites.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
0.768 USD | +0.73% | +2.68% | -26.31% |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-26.31% | 57.99L | |
+8.89% | 11TCr | |
+11.47% | 10TCr | |
-12.69% | 2.24TCr | |
-1.05% | 2.23TCr | |
-5.29% | 1.91TCr | |
-38.29% | 1.8TCr | |
-3.15% | 1.79TCr | |
+8.12% | 1.43TCr | |
+34.69% | 1.25TCr |
- Stock Market
- Equities
- LIPO Stock
- News Lipella Pharmaceuticals Inc.
- Lipella Pharmaceuticals Inc. Announces FDA Clearance of IND for LP-310 for Oral Lichen Planus